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Phase II Trial of Temsirolimus for Relapsed/Refractory
Primary CNS Lymphoma
Agnieszka Korfel, Uwe Schlegel, Ulrich Herrlinger, Martin Dreyling, Christian Schmidt, Luisa von Baumgarten,
Antonio Pezzutto, Thomas Grobosch, Sied Kebir, Eckhard Thiel, Peter Martus, and Philipp Kiewe
A B S T R A C T
Purpose
In this phase II study (NCT00942747), temsirolimus was tested in patients with relapsed or
refractory primary CNS lymphoma (PCNSL).
Patients and Methods
Immunocompetent adults with histologically confirmed PCNSL after experiencing high-dose
methotrexate-based chemotherapy failure who were not eligible for or had experienced high-
dose chemotherapy with autologous stem-cell transplant failure were included. The first cohort
(n = 6) received 25 mg temsirolimus intravenously once per week. All consecutive patients received
75 mg intravenously once per week.
Results
Thirty-seven eligible patients (median age, 70 years) were included whose median time since their
last treatment was 3.9 months (range, 0.1 to 14.6 months). Complete response was seen in five
patients (13.5%), complete response unconfirmed in three (8%), and partial response in 12 (32.4%)
for an overall response rate of 54%. Median progression-free survival was 2.1 months (95% CI, 1.1
to 3.0months). Themost frequent Common Toxicity Criteria$ 3° adverse event was hyperglycemia
in 11 (29.7%) patients, thrombocytopenia in eight (21.6%), infection in seven (19%), anemia in four
(10.8%), and rash in three (8.1%). Fourteen blood/CSF pairs were collected in nine patients (10 pairs
in five patients in the 25-mg cohort and four pairs in four patients in the 75-mg cohort). The mean
maximum blood concentration was 292 ng/mL for temsirolimus and 37.2 ng/mL for its metabolite
sirolimus in the 25-mg cohort and 484 ng/mL and 91.1 ng/mL, respectively, in the 75-mg cohort.
Temsirolimus CSF concentration was 2 ng/mL in one patient in the 75-mg cohort; in all others, no
drug was found in their CSF.
Conclusion
Single-agent temsirolimus at a weekly dose of 75 mg was found to be active in relapsed/refractory
patients with PCNSL; however, responses were usually short lived.
J Clin Oncol 34:1757-1763. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Approximately one-quarter of patients with primary
CNS lymphoma (PCNSL) do not respond to first-
line therapy and more than one half relapse.1 The
prognosis of patients with refractory/relapsed PCNSL
is poor, and therapeutic options remain limited.
Whole-brain radiotherapy (WBRT) is probably
the most effective salvage treatment with response
rates of 60% to 79% and median overall survival
(OS) of 10.9 to 16 months after retreatment.2,3
However, WBRTexposes patients to a higher risk
of late neurotoxicity than chemotherapy.4,5 Thus,
salvage chemotherapy is frequently preferred,
particularly in patients with good performance status
and who responsed well to previous chemotherapy.
Single-agent chemotherapy/immunotherapy
with topotecan,6,7 rituximab,8 temozolomidewith or
without rituximab,9-11 ifosfamide- and/or etoposide-
based polychemotherapy,12-14 and yttrium-90
(90Y)–labeled ibritumomab tiuxetan15 have been
evaluated as salvage treatment in several small and
frequently retrospective analyses. A wide range
of response rates from 14% to 53% have been
observed with, not surprisingly, a much lower
response rate when more stringent response cri-
teria were used, such as response confirmation.11
The median progression-free survival (PFS) was
uniformly short (2 to 5 months). Rechallenge with
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high-dose methotrexate (HDMTX) is an option for patients who
experienced long-term remission after primary HDMTX therapy.16
High-dose chemotherapy with an autologous stem-cell trans-
plant (HD-ASCT) might be considered for younger patients who
can tolerat intensive therapy. In a retrospective trial, 79 patients with
a median age of 52 years who experienced HDMTX-based therapy
failure (including, however, 11 patients with partial remission [PR])
received high-dose cytarabine-based salvage treatment followed by
high-dose chemotherapywith thiotepa, busulfan, cyclophosphamide,
and ASCT. The 5-year probability of disease-free survival was 49.5%,
but six patients who received HD-ASCT died. Seven patients died
from severe CNS toxicity.17
Mammalian target of rapamycin (mTOR) is a ubiquitously
expressed serine-threonine protein kinase that belongs to the
phosphoinositide 3-kinase (PI3K)—related kinase family. The
PI3K/AKT/mTOR pathway is a critical switch constituting the core
of a highly conserved evolutionary pathway that adjusts protein
synthesis to regulate cell growth and proliferation by integrating
signals arising from growth factors, hormones, nutrients, and
energy metabolism.18 There is preclinical and clinical evidence that
the mTOR pathway is important in the tumor biology of aggressive
lymphoma. In a randomized phase III trial19 of patients with
relapsed/refractory mantle cell lymphoma, the response rate to
temisirolimus 175 mg every 3 weeks followed by 75 mg weekly was
22% and significantly higher when compared with investigator’s
choice; the median PFS was 4.8 months. In a trial of patients with
different aggressive non-Hodgkin lymphomas, the response rate
with diffuse large B-cell lymphoma (DLBCL) to everolimus was
30%.20 In another trial,21 the response rate to temsirolimus in the
refractory DLBCL subpopulation was 28.1% (complete response
[CR] rate, 12.5%) with a median PFS of 2.6 months and OS of
7.2 months.
In a study on relapsedmalignant glioma, high concentrations of
temsirolimus were found in brain tumor specimens with a brain/
blood ratio of 1.43 for temsirolimus and 0.84 for its metabolite
sirolimus.22
Based on its activity and relatively good tolerability in patients
with refractory/relapsed aggressive lymphoma, and its ability to
penetrate the brain tumor tissue, we decided to evaluate temsirolimus
in patients with refractory/relapsed PCNSL.
PATIENTS AND METHODS
Inclusion Criteria
Eligibility criteria included patients older than 18 years with PCNSL
proven histologically or cytologically (in the CSF) and with evidence of a
relapse or progression (onmagnetic resonance imaging or in the CSF) after
HDMTX-based primary chemotherapy; the time interval since the
patient’s last chemotherapy had to be $ 3 weeks and their Eastern
Cooperative Oncology Group performance score # 2. Criteria also
included adequate renal function (glomerular filtration rate. 30 mL/min),
neutrophils . 1,500/mL, thrombocytes . 80,000/mL, bilirubin , 1.5-fold
the upper limit of normal, transaminases , 33 the upper limit of normal,
and the patient’s signed informed consent. Exclusion criteria were secondary
CNS lymphoma, eligibility for more intensive treatment such as HD-ASCT,
uncontrolled infection, HIV positivity, serious comorbidity, other active
malignant disease, concomitant treatment with potent CYP3A4/5 inductors
or inhibitors, and pregnancy/breastfeeding. The protocol was approved by
the responsible ethics committees. Study conduct followed International
Conference on Harmonization Guidelines for Good Clinical Practice,
including written informed consent and data monitoring. Baseline assess-
ments included physical and neurologic examination, cranial magnetic
resonance imaging (spinal on clinical suspicion only), and ophthalmologic
and CSF examination.
Study Design and Treatment
This was a phase II, nonrandomized, open-label study with a two-
stage design using single-agent temsirolimus in patients with relapsed or
refractory PCNSL. In the first stage, patients were treated with temsiro-
limus 25 mg intravenously once per week with clemastine premedication.
In case of Common Toxicity Criteria grades 3 to 4 toxicity, three additional
patients were to be treated with the same dose. If no Common Toxicity
Criteria grades 3 to 4 toxicity were observed, all following patients were
treated with 75 mg once per week. Treatment was administered until
progressive disease (PD), unacceptable toxicity, death, or the patient’s or
investigator’s decision to terminate participation, for a maximum of
12 months. Five dose reductions for toxicity were permitted (to 60, 40, 30,
20, 15 mg), after which treatment was discontinued. Interruption of
temsirolimus for longer than 3 weeks also resulted in discontinuation.
Evaluation During Treatment
Safety assessments included physical examinations, adverse event
monitoring, and laboratory parameter changes before each infusion.
Adverse events were graded using the National Cancer Institute Common
Terminology Criteria for Adverse Events (version 3.0). Response assess-
ment was performed after 4 weeks and every 8 weeks thereafter. Addi-
tionally, response assessment was recommended at each time point when
progression was suspected. After discontinuing therapy, patients com-
pleted an end-of-treatment visit 30 days after their last temsirolimus dose.
In patients with PR or CR, remission status was evaluated every 3 months.
Survival data were collected every 3 months for up to 2 years from start of
study treatment or until study closure.
Serum and CSF samples for pharmacokinetic analysis were obtained
immediately after the first, fourth, and twelfth infusion. The samples were
immediately frozen at 280°C and stored until measurement.
Drug concentration was measured using high-performance liquid
chromatography with mass spectrometric detection; the lower limit of
detection was 1 ng/mL.
End Points and Statistical Analysis
The primary end point was overall response rate (ORR), which
included CR, CR unconfirmed (uCR), and PR. Secondary end points
included penetration of temsirolimus into the CSF, toxicity, PFS, and OS.
Response was defined according to the criteria of the International Primary
CNS Lymphoma Cooperative Group.23 PFS was calculated from the time
of enrollment in the study until progression, relapse, or death. OS was
calculated from the time of enrollment in the study until death.
Because no data on temsirolimus in PCNSL were available and
inclusion of mostly elderly patients unfit for heavy pretreatment was
intended, a Simon optimum design24 was used for patients’ number
calculation (to minimize the risk that too many patients were treated with
ineffective therapy) with an unacceptable ORR of 0.05 (p0 in the termi-
nology of Simon) and a favorable ORR of 0.20 (p1 in the terminology of
Simon), and error probabilities of a = b = 0.10. Based on these hypotheses,
12 patients were needed for stage 1 and further accrual was stopped if less
than one patient responded. The second stage of the trial was planned to
enroll 25 additional patients. After termination of this study stage, the
therapy was considered ineffective if fewer than four patients responded.
Results are expressed as percentages or medians and ranges. PFS and
OS were calculated using the Kaplan-Meier method. For the ORR, the
median PFS and the median OS, two-sided 95% confidence limits are
given. The CIs of median PFS and OS were estimated as described by
Collett et al.25 For the ORR, PFS, and OS, two-sided 95% confidence limits
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are given. Analysis was done using SPSS software, version 22 (SPSS,
Chicago, IL) and R (2.9.2).
RESULTS
Patient Characteristics
Between September 2009 and November 2014, 37 patients
were enrolled at four German centers (Table 1). With the exception
of one patient with T-cell lymphoma, all patients had DLBCL. The
vast majority of patients had intermediate- or high-risk disease
according to the Memorial Sloan Kettering Cancer Center score.26
Patients had received a median of one prior therapy (range, one to
five therapies) comprising HDMTX in all patients and high-dose
cytarabine in 11 (30%). Two patients (5%) were pretreated with
WBRT, three patients (8%) with HD-ASCT, and four patients
(11%) with both. The median time since last pretreatment was
3.9 months.
Therapy and Efficacy
Among the first three patients who were given 25 mg tem-
sirolimus, two had grade 3 toxicity (one patient had diarrhea,
thrombocytopenia, and leukopenia with pneumonia; one patient
had pneumonia). Thus, an additional three patients were treated
with the same dose. In these patients, no grade 3 to 4 toxicity was
observed, and there was a PR in one patient. Thus, per protocol, the
study was continued with 75 mg temsirolimus once per week.
A total of 296 infusions were given: 42 at the 25-mg dose level
and 254 at the 75-mg dose level. The median number of infusions
per patient was six (range, one to 28 infusions). Dose reductionwas
performed three times at the 25-mg dose level and 50 times at the
75-mg dose level. Infusions were delayed . 1 day in 47 cases.
Five patients (13.5%) achieved CR, three (8%) uCR, and 12
(32.4%) PR for an ORR of 54% (95% CI, 37% to 71%) The details
on all responders are given in Table 2 and an example of response is
shown in Figure 1. Seven patients (18.9%) had stable disease (SD),
five (13.5%) had PD, and five (13.5%) had no response evaluation.
Of the six patients pretreated with WBRT, only one responded
with a CR (three had SD, one had PD, and one had no response
evaluation). Of the seven patients pretreated with HD-ASCT, two
responded with CR and one with uCR (two had SD, one had PD,
and one had no response evaluation). One of the responding
patients was taking steroids at the time of response evaluation.
Seven patients had not been taking steroids for 1 week, three for
2 weeks, two for 3 weeks, and seven for . 3 months. The median
time to response was 3.5 weeks.
The median PFS was 2.1 months (95% CI, 1.1 to 3.0 months)
with 1-year PFS of 5.4% (95% CI, 0% to 11.2%; Fig 2A). The
median OS was 3.7 months (95% CI, 1.5 to 5.8 months) with
1-year OS of 19% (95% CI, 6.1% to 31.7%) and 2-year OS of
16.2% (95% CI, 4.1% to 28.4%; Fig 2B). Seven patients received
further treatment after study termination. Two patients received
topotecan. Two patients received topotecan plus intrathecal che-
motherapy. Two patients were treated with WBRTand one patient
was treated with rituximab plus chemotherapy intrathecally fol-
lowed by fludarabine plus cyclophosphamide plus busulfan plus
thiothepa and an allogenic stem-cell transplant.
Safety
Toxicity is summarized in Table 3. The most frequent tox-
icities were hyperglycemia, bone marrow suppression, infections
(mostly pneumonias), and fatigue. There were a total of 28 severe
adverse events in 21 patients: 14 infectious episodes, four hospital
admissions because of clinical worsening due to PD, two cases of
deep venous thrombosis, two cases of hyperglycemia, and one case
each of seizures, grade 4 thrombocytopenia, drug fever, hypona-
tremia, renal insufficiency, and atrial fibrillation. A total of 10
patients—one with CR, three with PR, two with SD, one with PD,
and three with unknown remission status—died within 4 weeks
after administration of last study therapy: five due to toxicity
(pneumonia in two patients and GI infection with sepsis, sepsis
without focus, and cerebral bleeding in one patient each) and five
due to tumor progression.
CSF Penetration of Temsirolimus and Sirolimus
Fourteen blood/CSF pairs were collected in nine patients:
10 pairs in five patients in the 25-mg cohort and four pairs in four
patients in the 75-mg cohort. The mean maximum blood con-
centration was 292 ng/mL for temsirolimus and 37.2 ng/mL for
sirolimus in the 25 mg cohort and 484 ng/mL for temsirolimus and
91.1 ng/mL for sirolimus in the 75-mg cohort. In one patient in
the 75-mg cohort, a marginal temsirolimus CSF concentration of
Table 1. Demographic and Patient Characteristics
Characteristic Patients* %
Age, years, median (range) 70 (22-83)
Female/male 19/18 51/49
ECOG performance status, median (range) 2 (0-2)
MSKCC score
1 2 5
2 29 78
3 6 16
Pretreatment
High-dose methotrexate 37 100
Monotherapy 5 13.5
Combination† 32 86.5
Rituximab 21 57
High-dose cytarabine 11 30
High-dose chemotherapy followed
by ASCT
7 19
Whole-brain radiotherapy 6 16
Topotecan 6 16
Temozolomide 2 5
R-CHOP 1 3
Cytarabine, methotrexate, dexamethasone i.th. 1 3
No. of previous treatment regimens
1-2 29 78
3-5 8 22
Median time since last pretreatment, months 3.9
Lymphoma localization
Parenchymal only 30 81
Meningeal only 4 11
Combined 3 8
Abbreviations: ASCT, autologous stem-cell transplantation; ECOG, Eastern
Cooperative Oncology Group; i.th., intrathecally; MSKCC, Memorial Sloan Ket-
tering Cancer Center; R-CHOP, rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone.
*Values are expressed as No. of patients unless otherwise stated.
†Mostly combined with ifosfamide.
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Table 2. Responders’ Characteristics
Patient Age
(Years)
No. of
Pretreatments
Pretreatment
Regimens
Steroid-Free Interval
Before First Response
Assessment
Successive
Assessments
Response, Reason
for Termination
of Study
PFS
(months)
OS
(months)
69 1 HDMTX+ifosfamide No steroids 1 PR 2.7 3.6
2 PD
75 1 HDMTX No steroids 1 PR 8.1 . 59.2
2 uCR
3 CR
4 CR
5 CR
6 PD
81 1 HDMTX 1 week 1 PR 5.2 7.1
2 PR
3 PR
4 PD
68 1 HDMTX+rituximab 3 weeks 1 PR 3.1 . 56.1
2 PR
3 PR
4 PD
61 2 1. HDMTX+rituximab,
HDAraC+HD-ASCT+
2. AraC+MTX+
prednisolone icv
1 week 1 uCR 2.6 18.6
2 PD
67 2 1. HDMTX+ifosfamide
2. TT+HDAraC
Continuous steroids 1 PR, thrombocytopenia 1.3 1.4
69 4 1. HDMTX
2. HDMTX + ifosfamide
3. topotecan
4. HDAraC
No steroids 1 PR 2.0 2.0
2 PD
68 1 HDMTX+ifosfamide+
rituximab
No steroids 1 PR 3.8 . 52.5
2 uCR
3 PD
78 1 HDMTX+ifosfamide 2 weeks 1 PR 2.1 10.0
2 PD
72 1 HDMTX+rituximab 1 week 1 PR 15.8 . 45.3
2 2. PR
3 CR, patient’s decision
77 1 HDMTX+ifosfamide No steroids 1 CR 3.1 4.7
2 CR
3 PD
43 1 HDMTX+ifosfamide,
HDAraC+HD-ASCT
1 week 1 1. PR 44.4+ . 44.4
2 2. PR
3 CR, patient’s decision
72 2 1. HDMTX+ifosfamide
2. ifosfamide
2 weeks 1 1. PR 2.8 8.5
2 2. PD
81 2 1. HDMTX+ifosfamide
2. topotecan
No steroids 1 PR, late neurotoxicity 2.0 2.0
73 1 HDMTX+ifosfamide+
rituximab
No steroids 1 PR 4.1 5.3
2 PR
3 PD
63 2 1. HDMTX+ifosfamide+
rituximab
2 weeks 1 PR, late neurotoxicity 2.9 2.9
2. HDAraC+TT
77 1 HDMTX+ifosfamide+
HDAraC+rituximab
1 week 1 uCR, pneumonia 1.4 1.4
83 2 1. HDMTX+ifosfamide+
HDAraC+rituximab
2. temozolomide
1 week 1 PR 3.4 3.4
2 PD
72 1 HDMTX+ifosfamide+
cyclophosphamide+
HDAraC
3 weeks 1 PR 7.9 10.9
2 PR
3 PR
4 PD
22 3 1. HDMTX+ifosfamide+
HDAraC+rituximab
2. temozolomide
1 week 1 CR 6.3 . 20.5
2 CR
3 PD
Abbreviations: AraC, cytarabine; CR, complete remission; HDAraC, high-dose cytarabine; HD-ASCT, high-dose chemotherapy followed by autologous stem-cell
transplant; HDMTX, high-dose methotrexate; icv, intraventricular; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial remission; TT,
thiotepa; uCR, unconfirmed remission; WBRT, whole-brain radiotherapy.
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2 ng/mL was found; in all others, no drug was detected in the CSF
(Appendix Table A1, online only).
DISCUSSION
This is the first completed prospective trial of a targeted agent in
PCNSL. Conducting prospective studies of patients with refractory/
relapsed PCNSL is particularly difficult due to the frequently
aggressive course of this disease with rapid deterioration of patients’
performance status, often preventing physicians from enrolling them
in prospective trials and sometimes from providing any treatment
at all.
Response rate in the present trial is in the upper range of
responses in other studies on refractory/relapsed PCNSL,6-15 which
is remarkable considering the accumulation of negative prognostic
factors such as relatively old age, poor Memorial Sloan Kettering
Cancer Center score, heavy pretreatment (including HD-ASCTand
WBRT), and short interval since last pretreatment. Comparison of
studies on refractory/relapsed PCNSL is, however, difficult due to
use of different response criteria, wide spectrum of patients’ ages,
heterogeneous pretreatment, and a frequent lack of detailed infor-
mation on the potentially confounding use of steroids. Unfortu-
nately, the relatively high response rate in the current study did not
translate into a longer PFS, whichwas comparable with other studies.
A possible explanation could be that the effects of targeted agents
in PCNSL, which are currently almost unknown, are different from
those seen with classical chemotherapy. The short life span of the
responses indicates that temsirolimus is active in PCNSL, but its
activity is often transient, probably due to development of tumor
cell resistance. Thus, incorporation of temsirolimus into earlier
treatment lines or combining it with other cytostatic drugs or
rituximab (as is being done for systemic DLBCL in an ongoing
study [NCT0165306727] and has been done in other lymphomas28,29)
seems worth consideration. Given the toxicity observed in this study,
this should be done in younger patients who are fitter for treatment
and using primary antibiotic prophylaxis. Interestingly, a synergism
between temsirolimus and MTX has been demonstrated in vitro in
cell lines of acute lymphoblastic leukemia and in vivo in a mouse
model,30 suggesting the evaluation of this combination in patients
with untreated PCNSL or in patients relapsing after long remission
duration to first HDMTX treatment.
Because of the relatively low response rate of relapsed/refractory
systemic DLBCL of 20% to 30% and the lack of registration for
malignant lymphoma inmany countries including the United States,
mTOR inhibitors have not been incorporated into the treatment of
these patients. The response rate of 54% in the present trial was
higher compared with studies on systemic DLBCL. Given that
PCNSL biology is not fully understood, we can only speculate about
Fig 1. Complete response to temsirolimus in a 67-year-old patient. (A) Relapse
after high-dose methotrexate and ifosfamide. (B) After eight infusions of tem-
sirolimus 75 mg/m2 intravenously once per week.
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Fig 2. (A) Progression-free survival in all patients (N = 37). (B) Overall survival in all patients (N = 37).
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the reason for its higher sensitivity to mTOR inhibitors compared
with systemic DLBCL. Based on gene expression patterns, PCNSL
mostly corresponds to the activated B-cell (ABC) subtype of
DLBCL.31 Unfortunately, the available efficacy data of temsirolimus
in DLBCL did not differentiate between ABC and non-ABC
subtype. However, ibrutinib, an upstream inhibitor of the B-cell
receptor pathway, has shown striking efficacy, especially in the
ABC subtype.32
Toxicity observed in this trial was considerable, with 13.5%
treatment-associated mortality. This underscores the compro-
mised condition of patients with relapsed/recurrent PCNSL who
are not eligible for HD-ASCT or who have experienced treatment
failure. Infections, mostly pneumonias, were among the most
frequent toxicities and were also observed with 25mg temsirolimus
and without leukopenia. It cannot be excluded that some of the
patients classified as having pneumonia in fact had pneumonitis, a
well-known adverse effect of mTOR inhibitors, which can also
present with fever, cough, shortness of breath, and pulmonary
infiltrates on chest x-ray. The treatment of these patients in our
study targeted both conditions and included both antibiotics and
steroids. The frequency of severe infections of 18.9% was higher
than the 9% in the study by Hess et al.19 This could be due to the
frequent pretreatment with steroids and poorer performance status
of our patients, with only 40.5% of patients with Eastern Coop-
erative Oncology Group grades 0 to 1 compared with 91% in the
study by Hess et al. Severe hematotoxicity was less frequent in the
current study compared with patients with mantle cell lymphoma
treated with 75 mg temsirolimus once per week (grades 3 to 4
thrombocytopenia 22% v 59% in the study by Hess et al, grades 3
to 4 anemia 11% v 20%). This might have been due to a relatively
high proportion of patients (44%) with bone marrow infiltration
and higher temsirolimus dose in the induction phase in the study
by Hess et al. Although we did not check for bone marrow
involvement in our patients, we can exclude it in the vast majority
of them based on the known relapse/progression pattern of
PCNSL, which almost exclusively involves the CNS.
There is an obvious discrepancy between temsirolimus
activity and lack of detectable concentration of the drug and its
main metabolite in the CSF. One explanation could be that CSF
and brain parenchyma represent different compartments, and CSF
levels do not necessarily reflect brain parenchyma concentrations.
Moreover, there is a breakdown of the normal blood-brain barrier
within the tumor bulk, allowing penetration of drugs which do not
cross the intact blood-brain barrier. High drug concentrations in
the tumor tissue and the adjacent brain, with no or barely meas-
urable CSF concentrations, have been reported for several cytostatic
agents such as platinum and epidophylotoxins.33 However, the
limited data available suggest that drug concentrations in the brain
tissue usually drop with increasing distance from the tumor, to
levels that are frequently too low to eradicate infiltrating tumor
cells.
Frequent administration of steroids before response assess-
ment has to be considered a confounding factor for response
evaluation due to their lymphotoxic effect, which may persist for
several weeks after discontinuation. Only in seven of 20 responders
not taking steroids for at least 3 months before first response
assessment could the therapeutic effect be attributed solely to
temsirolimus. Another limitation was the preferential inclusion of
elderly patients whose initial treatment is frequently not according
to the current standards used in younger patients. Generalization
of our results to unselected patients with PCNSL should thus be
viewed with caution.
In summary, temsirolimus proved active in relapsed/refractory
PCNSL. Although most responses were short lived, some patients
achieved long-term control. Thus, further evaluation in combina-
tion with other drugs seems reasonable. However, one has to be
aware of the risk of hematotoxicity and infections necessitating
primary antibiotic prophylaxis. Definition of biomarkers allowing
identification of potential responders and those who are at par-
ticular risk for toxicity would be highly desirable.
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Table 3. Maximal Toxicity Per Patient
Toxicity
All Grades
Patient No. (%)
Grade 1-2
Patient No. (%)
Grade 3-4
Patient No. (%)
Hematologic
Thrombocytopenia 23 (62.2) 15 (40.5) 8 (21.6)
Anemia 22 (59.5) 18 (48.6) 4 (10.8)
Leukopenia 22 (59.4) 20 (54) 2 (5.4)
Nonhematologic
Hyperglycemia 31 (83.8) 20 (52.6) 11* (29.7)
Transaminases elevation 16 (43.2) 15 (40.5) 1 (2.7)
Fatigue 16 (43.2) 14 (37.8) 2 (5.4)
Skin toxicity 13 (35) 10 (27) 3 (8.1)
Infection 12 (32.4) 5 (13.5) 7 (18.9)
Creatinine elevation 11 (29.7) 10 (27) 1 (2.7)
Stomatitis 10 (27) 10 (27) 1 (2.7)
Nausea 5 (13.5) 5 (13.5) 2 (5.4)
Vomiting 2 (5.4) 2 (5.4) 1 (2.7)
Diarrhea 2 (5.4) 1 (2.7) 1 (2.7)
*Six patients were taking steroids.
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Appendix
Table A1. Concentrations of Temsirolimus and Sirolimus in Blood and CSF of Individual Patients
Patient
Temsirolimus
Dose (mg)
Infusion
No.
Temsirolimus (ng/mL) Sirolimus (ng/mL)
Blood CSF Blood CSF
0101 25 1 399 , 1 13.1 , 1
2 675 , 1 19.0 , 1
4 258 , 1 18.4 , 1
0102 25 1 181 , 1 105 , 1
0103 25 1 315 , 1 28.9 , 1
4 130 , 1 78.8 , 1
0104 25 1 217 , 1 13.2 , 1
3 203 , 1 15.7 , 1
6 256 , 1 18.4 , 1
0105 25 1 287 , 1 61.7 , 1
0107 75 1 565 , 1 97.6 , 1
0110 75 1 813 , 1 79.4 , 1
0111 75 1 237 2 65.4 , 1
0112 75 1 322 , 1 122 , 1
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